Published financial brief
1253B
GUARDIAN PHARMACY SERVIS INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
3 data notes
- Only 3 of 5 periods.
- Input provenance requires review.
- One or more values are unavailable.
Exact-period record
Fundamentals
3 reported periods
| Metric | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|
| Financial statements | |||
| RevenueUSD millions | 908.9 | 1,046.2 | 1,228.4 |
| Cost of goods soldUSD millions | 713.9 | 828.3 | 973.7 |
| Selling, general and administrative expenseUSD millions | 122.7 | 135.3 | 293.4 |
| Depreciation and amortizationUSD millions | 16.6 | 18.2 | 19.8 |
| Net incomeUSD millions | 35.4 | 23.9 | -87.3 |
| Operating profit (EBIT)USD millions | 55.7 | 64.4 | -58.5 |
| Income taxesUSD millions | 0 | 0 | 4.6 |
| Short-term debtUSD millions | 16.3 | 23.1 | 10.6 |
| Long-term debtUSD millions | 46.6 | 46 | 26.7 |
| Cash and equivalentsUSD millions | 0.6 | 0.8 | 4.7 |
| ReceivablesUSD millions | 67.8 | 77.3 | 97.2 |
| InventoryUSD millions | 41.4 | 36.7 | 40.6 |
| PayablesUSD millions | 78.1 | 85.6 | 102.4 |
| Net property, plant and equipmentUSD millions | 65.2 | 73.2 | 79 |
| Capital expenditureUSD millions | 16.8 | 14.6 | 16.4 |
| Operating cash flowUSD millions | 48.5 | 70.8 | 58 |
| Prepaid expensesUSD millions | 0 | 0 | 0 |
| AccrualsUSD millions | 13.9 | 17 | 14.4 |
| EBITDAUSD millions | 72.3 | 82.6 | -38.7 |
| Working capitalUSD millions | 8 | -8.4 | 7.9 |
| Working capital requirementUSD millions | 31.2 | 28.4 | 35.3 |
| Total debtUSD millions | 63 | 69.2 | 37.3 |
| Free cash flowUSD millions | 31.8 | 56.3 | 41.6 |
| Unlevered free cash flowUSD millions | 55.5 | 70.9 | -62 |
| Returns and ratios | |||
| ROICratio | 25% | 28.5% | -21.8% |
| Pre-tax ROICratio | 25% | 28.5% | -21.8% |
| Effective tax rateratio | 0% | 0% | 0% |
| Revenue growthratio | —missing | 15.1% | 17.4% |
| EBIT / Revenueratio | 6.1% | 6.2% | -4.8% |
| Revenue / Invested capitalmultiple | 4.08× | 4.64× | 4.59× |
| Cogs Over Revenuesratio | 78.5% | 79.2% | 79.3% |
| Sga Over Revenuesratio | 13.5% | 12.9% | 23.9% |
| Da Over Revenuesratio | 1.8% | 1.7% | 1.6% |
| Nfa Over Revenuesratio | 7.2% | 7% | 6.4% |
| Wcr Over Revenuesratio | 3.4% | 2.7% | 2.9% |
| Debt Over Ebitdamultiple | 0.87× | 0.84× | —missing |
| St Debt Over Cashmultiple | 26.92× | 30.75× | 2.28× |
| Interest Over Ebitdamultiple | 0.03× | 0.03× | —missing |
| Interest Over Nocf Nicfmultiple | 0.06× | 0.05× | 0.08× |
| Nsf Over Wcrmultiple | 0.5× | 0.79× | 0.17× |
Ask this snapshot
Research assistant
1253B · annualSnapshot 828e0035
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000